Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15690003 | 0.81 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2 | |
| SCHEMBL28566661 | 0.81 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12798307 | 0.81 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1TNFPRMT5 | |
| Hydrochloric Acid SCHEMBL28566253 | 0.79 | KDM4E (0.43) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL18817029 | 0.78 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2 | |
| SCHEMBL15690069 | 0.78 | USP7 (0.30) | — | |
| SCHEMBL18536813 | 0.76 | KDM4E (0.43) | KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2 | |
| SCHEMBL18378571 | 0.75 | PDE10A (0.43) | KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2 | |
| SCHEMBL15538674 | 0.75 | PDE10A (0.45) | KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2 | |
| SCHEMBL5055837 | 0.74 | ALDH1A1 (0.50) | KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | KDM4E 3824/4885SMN1; SMN2 1258/4885ALDH1A1 2699/4885 |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | KDM4E 898/4885SMN1; SMN2 3790/4885ALDH1A1 794/4885 |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | KDM4E 2567/4885SMN1; SMN2 1182/4885ALDH1A1 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.